Comparison of EMA and FDA guidelines for drug interactions: An overview

References

• Jankovic SM. Handbook of pharmacology and toxicology. 4th ed. Kragujevac: Faculty of Medical Sciences, University of Kragujevac; 2013
   Google Scholar
• Mehta N, deGoma EM. Pharmacologic interactions of multidrug therapy for dyslipidemia. Curr Atheroscler Rep 2013;15:303
   PubMedGoogle Scholar
• Andrade C. Drug interactions in the treatment of depression in patients with ischemic heart disease. J Clin Psychiatry 2012;73:e1475–7
   PubMedGoogle Scholar
• Heuberger R. Polypharmacy and food-drug interactions among older persons: a review. J Nutr Gerontol Geriatr 2012;31:325–403
   PubMedGoogle Scholar
• Cascorbi I. Drug interactions – principles, examples and clinical consequences. Dtsch Arztebl Int 2012;109:546–55
   PubMed Web of Science ®Google Scholar
• Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, et al.; The EMIR Study Group on behalf of the French network of pharmacovigilance centres. Incidence of hospital admissions due to adverse drug reactions in France: The EMIR study. Fundam Clin Pharmacol 2014. (Epub ahead of print)
   Google Scholar
• Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products (CHMP). European Medicines Agency, CPMP/EWP/560/95/Rev. 1 Corr., 2013. London, UK: European Medicines Agency. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• Guidance for Industry: Drug Interaction Studies – Study design, data analysis, implications for dosing, and labeling recommendations, draft guidance. Silver Spring: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2012. Available online at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, accessed 17 June 2014
   Google Scholar
• Jung JA, Kim JR, Kim TE, et al. Effect of food on the pharmacokinetic properties of the oral sarpogrelate hydrochloride controlled-release tablet in healthy male Korean subjects. Clin Ther 2013;35:1038–44
   PubMed Web of Science ®Google Scholar
• Wire MB, Bruce J, Gauvin J, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther 2012;34:699–709
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1–26
   PubMedGoogle Scholar
• Chin TF, Lach JL. Drug diffusion and bioavailability: tetracycline metallic chelation. Am J Hosp Pharm 1975;32:625–9
   PubMedGoogle Scholar
• Mungall D, Wong YY, Talbert RL, et al. Plasma protein binding of warfarin: methodological considerations. J Pharm Sci 1984;73:1000–1
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Determination of hepatic clearance with the account of drug-protein binding kinetics. J Pharm Sci 2012;101:3936–45
   PubMed Web of Science ®Google Scholar
• Prokai-Tatrai K, Prokai L. Prodrug design for brain delivery of small- and medium-sized neuropeptides. Methods Mol Biol 2011;789:313–36
   PubMedGoogle Scholar
• Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol 2012;5:569–85
   PubMed Web of Science ®Google Scholar
• Pochet L, Servais AC, Farcas E, et al. Determination of inhibitory potency of argatroban toward thrombin by electrophoretically mediated microanalysis. Talanta 2013;116:719–25
   PubMed Web of Science ®Google Scholar
• Espié P, Tytgat D, Sargentini-Maier ML, et al. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 2009;41:391–407
   PubMed Web of Science ®Google Scholar
• Novotna A, Srovnalova A, Svecarova M, et al. Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines. PLoS One 2014;9:e98711
   PubMedGoogle Scholar
• Einolf HJ, Chen L, Fahmi OA, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther 2014;95:179–88
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Raucy JL, Ponce E, et al. Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships. Drug Metab Dispos 2012;40:2204–11
   PubMed Web of Science ®Google Scholar
• Einolf HJ, Chen L, Fahmi OA, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther 2014;95:179–88
   PubMed Web of Science ®Google Scholar
• Tsuji A. Transporter-mediated drug interactions. Drug Metab Pharmacokinet 2002;17:253–74
   PubMedGoogle Scholar
• Soldner A, Benet LZ, Mutschler E, Christians U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol 2000;129:1235–43
   PubMed Web of Science ®Google Scholar
• Chu X, Cai X, Cui D, et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 2013;41:668–81
   PubMed Web of Science ®Google Scholar
• Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78:154–67
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Chu X, Gibson C, et al. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J 2013;15:629–45
   PubMed Web of Science ®Google Scholar